Retifanlimab-dlwr (Zynyz)
Dilution requiredFull monograph review pending
U.S. label preparation
Zynyz · Dilution required
- Preparation
- Dilute the prescribed dose with 0.9% sodium chloride or 5% dextrose to a final concentration of 1.4-10 mg/mL.
- Administration and handling
- Gently invert the bag and use the infusion equipment specified in section 2.3.
Product and source details
Incyte Corporation · BLA761334
Product NDC: 50881-006
SPL effective 2026-05-18 | SPL version 18. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.